DNAPrint, Pharsight Enter Pharmacogenomics Partnership | GenomeWeb

NEW YORK. Aug. 24 – DNAPrint Genomics and scientific developer Pharsight have entered into a collaboration to empower DNAPrint’s pharmacogenomic product development, the company announced on Friday.

The terms of the contract, which is open-ended, call for Mountain View, Calif.-based Pharsight to provide DNAPrint with clinically phenotyped DNA specimens from patients who are taking medications known to elicit variable efficacy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.